相似文献
1
Trial watch: Success in amyloidosis trials supports potential of systemic RNAi.
Nat Rev Drug Discov. 2013 Nov;12(11):818. doi: 10.1038/nrd4165.
2
With Alnylam's amyloidosis success, RNAi approval hopes soar.
Nat Biotechnol. 2017 Nov 9;35(11):995-997. doi: 10.1038/nbt1117-995.
3
Safety and efficacy of RNAi therapy for transthyretin amyloidosis.
N Engl J Med. 2013 Aug 29;369(9):819-29. doi: 10.1056/NEJMoa1208760.
4
Treatment with patisiran of a patient with hereditary transthyretin-mediated amyloidosis with stage 3 polyneuropathy.
Muscle Nerve. 2021 Sep;64(3):E11-E13. doi: 10.1002/mus.27338. Epub 2021 Jun 9.
5
Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study.
Orphanet J Rare Dis. 2015 Sep 4;10:109. doi: 10.1186/s13023-015-0326-6.
6
Alnylam launches era of RNAi drugs.
Nat Biotechnol. 2018 Sep 6;36(9):777-778. doi: 10.1038/nbt0918-777.
7
A new era in the treatment of amyloidosis?
N Engl J Med. 2013 Aug 29;369(9):866-8. doi: 10.1056/NEJMe1308768.
8
Treatment success in hereditary transthyretin amyloidosis.
Nat Rev Neurol. 2018 Sep;14(9):509. doi: 10.1038/s41582-018-0048-1.
9
RNA-based therapies have their day.
EBioMedicine. 2018 Aug;34:1. doi: 10.1016/j.ebiom.2018.08.025.
10
RNAi therapeutics: an update on delivery.
Curr Opin Mol Ther. 2008 Apr;10(2):158-67.
引用本文的文献
1
Modulating inhibitors of transthyretin fibrillogenesis via sulfation: polychlorinated biphenyl sulfates as models.
Chem Biol Interact. 2015 Feb 25;228:1-8. doi: 10.1016/j.cbi.2015.01.002. Epub 2015 Jan 13.
Zotero 插件